Scholarlink

Background <p>There has never been a detailed assessment of the management of gestational diabetes (GDM) previously in the UK.</p> Methods <p>We conducted a national electronic survey (September 2022– June 2023) and mixed quantitative and qualitative analyses to evaluate glucose targets and glucose management in GDM across the UK. The response rate was 52% (73/141 National Health Service [NHS] trusts) with data covering&#xa0;83&#xa0;hospitals.</p> Results <p>Most hospitals use the National Institute for Health and Clinical Excellence (NICE) recommended glucose targets; the most common fasting target was 5.3&#xa0;mmol/L (<i>n</i> = 70 hospitals; 84%); and the post-prandial 7.8&#xa0;mmol/L 1-h target (<i>n</i> = 72; 92%) and 6.4&#xa0;mmol/L 2-h target (<i>n</i> = 40; 78%). Metformin is used as the preferred first-line option for post-prandial and fasting blood glucose reduction in 84% of hospitals (with Modified-release metformin used initially in 17%). Insulin is used as the preferred first line in 28% for fasting and 19% for post-prandial glucose.</p> <p>In components of management not covered by national guidelines, there is wide practice variation, including insulin preparations used, starting doses, and titration rates. Standard insulin initiation doses ranged from 1–12 units for meal-time insulin and 2–20 units for basal insulin. There was a 13-fold difference in insulin titration rates from 0.3 units/day up to 4 units/day. The maximum basal insulin dose achievable during the first six weeks of titration varied from 15 to 182 units.</p> Conclusions <p>In GDM glucose management components not covered by national guidelines there is wide practice variation; slow insulin titration in some hospital protocols is of particular concern.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The glucose management of gestational diabetes in the UK: a national survey

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月6日

查看全文
  • Isabelle K. Mayne,
  • Maximilian J. Levy,
  • Bijay Vaidya,
  • Andrew P. McGovern

摘要

Background

There has never been a detailed assessment of the management of gestational diabetes (GDM) previously in the UK.

Methods

We conducted a national electronic survey (September 2022– June 2023) and mixed quantitative and qualitative analyses to evaluate glucose targets and glucose management in GDM across the UK. The response rate was 52% (73/141 National Health Service [NHS] trusts) with data covering 83 hospitals.

Results

Most hospitals use the National Institute for Health and Clinical Excellence (NICE) recommended glucose targets; the most common fasting target was 5.3 mmol/L (n = 70 hospitals; 84%); and the post-prandial 7.8 mmol/L 1-h target (n = 72; 92%) and 6.4 mmol/L 2-h target (n = 40; 78%). Metformin is used as the preferred first-line option for post-prandial and fasting blood glucose reduction in 84% of hospitals (with Modified-release metformin used initially in 17%). Insulin is used as the preferred first line in 28% for fasting and 19% for post-prandial glucose.

In components of management not covered by national guidelines, there is wide practice variation, including insulin preparations used, starting doses, and titration rates. Standard insulin initiation doses ranged from 1–12 units for meal-time insulin and 2–20 units for basal insulin. There was a 13-fold difference in insulin titration rates from 0.3 units/day up to 4 units/day. The maximum basal insulin dose achievable during the first six weeks of titration varied from 15 to 182 units.

Conclusions

In GDM glucose management components not covered by national guidelines there is wide practice variation; slow insulin titration in some hospital protocols is of particular concern.